|Articles|July 7, 2022
- Pharmaceutical Executive-07-01-2022
- Volume 42
- Issue 7
Pharmaceutical Executive, July 2022 Issue (PDF)
Advertisement
Articles in this issue
about 4 years ago
The True Nature of Danger Behind IP Waiver Proposalabout 4 years ago
Cracking Down on Speaker Programsabout 4 years ago
Dynamic Compliance: The Best Defense for Pharmaabout 4 years ago
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOsabout 4 years ago
Breaking Down Barriersabout 4 years ago
Biotech Performance Glance—and Promising Ripples for Recoveryabout 4 years ago
If Non-Formulary Hospital, Price May Not Be the Rxabout 4 years ago
When It Comes To DE&I, Silence Is Deafeningabout 4 years ago
Asia’s Rise in The Global Pharma IndustryAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Artisan Partners’ Director Calls for Novartis Board Shake-Up
2
The Agentic AI Revolution in Biopharma
3
340B Under Pressure: Inside Pharma's Push for Greater Clarity
4
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
5